Asia

Covance expands Singapore central lab by 50%

Monday, April 22, 2013

Covance, a provider of drug development services, has completed the expansion of its central laboratory facility in Singapore to enhance the company’s current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest in Covance’s continued investment in Singapore, and an important element of the strategic investment plans for the Asia Pacific region that also includes recent growth in operations in China and Japan.

[Read More]

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

[Read More]

TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida’s proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

[Read More]